Inside Trade: Saria Tseng Sold 4,057 Shares of Monolithic Power Systems, Inc. (MPWR); Neurocrine Biosciences (NBIX)’s Sentiment Is 1.66

February 6, 2018 - By Shannon Black

Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States and internationally. The company has market cap of $7.21 billion. The companyÂ’s lead products include INGREZZA , a vesicular monoamine transporter 2 inhibitor (VMAT2) used for the treatment of movement disorders; elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that is in Phase III clinical trials used for womenÂ’s health; and opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trials used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with ParkinsonÂ’s disease. It currently has negative earnings. It is also developing NBI-640756 that is in Phase I clinical trials used for the treatment of essential tremor; and NBI-74788, which is in Phase I clinical trials used for the treatment of classic congenital adrenal hyperplasia.

VP & General Counsel, Saria Tseng is the Monolithic Power Systems Inc’s insider that sold shares of Monolithic Power Systems Inc, 4,057 to be precise. The sold shares were based on $113.9, with the insider trading deal having a market value near $461,906 USD. At the moment, Saria Tseng has a total of 262,669 shares or 0.63% of the Company’s total market cap.

Ratings analysis reveals 50% of Neurocrine Biosci’s analysts are positive. Out of 2 Wall Street analysts rating Neurocrine Biosci, 1 give it “Buy”, 0 “Sell” rating, while 1 recommend “Hold”. NBIX was included in 2 notes of analysts from October 18, 2016. The firm has “Buy” rating given on Tuesday, October 18 by Needham. The company was initiated on Tuesday, November 22 by Oppenheimer.

Analysts await Neurocrine Biosciences, Inc. (NASDAQ:NBIX) to report earnings on February, 13. They expect $-0.03 earnings per share, up 94.12% or $0.48 from last year’s $-0.51 per share. After $-0.13 actual earnings per share reported by Neurocrine Biosciences, Inc. for the previous quarter, Wall Street now forecasts -76.92% EPS growth.

Perceptive Advisors Llc holds 11.21% of its portfolio in Neurocrine Biosciences, Inc. for 4.79 million shares. Bb Biotech Ag owns 3.46 million shares or 5.87% of their US portfolio. Moreover, Great Point Partners Llc has 5.66% invested in the company for 475,000 shares. The New York-based Healthcor Management L.P. has invested 4.29% in the stock. Ghost Tree Capital Llc, a New York-based fund reported 225,000 shares.

Since January 1, 0001, it had 0 insider buys, and 14 sales for $9.77 million activity.

The stock decreased 2.21% or $1.84 during the last trading session, reaching $81.49. About 957,452 shares traded or 3.38% up from the average. Neurocrine Biosciences, Inc. (NBIX) has risen 12.51% since February 6, 2017 and is uptrending. It has underperformed by 4.19% the S&P500.

Since August 14, 2017, it had 0 insider purchases, and 13 sales for $9.90 million activity. Blegen Theodore also sold $18,670 worth of Monolithic Power Systems, Inc. (NASDAQ:MPWR) shares. Tseng Saria also sold $482,136 worth of Monolithic Power Systems, Inc. (NASDAQ:MPWR) on Tuesday, August 15. On Monday, October 9 Moyer James C sold $1.63M worth of Monolithic Power Systems, Inc. (NASDAQ:MPWR) or 15,000 shares. 1,693 Monolithic Power Systems, Inc. (NASDAQ:MPWR) shares with value of $194,119 were sold by Sciammas Maurice. Hsing Michael sold $1.92M worth of Monolithic Power Systems, Inc. (NASDAQ:MPWR) on Monday, August 14.

Monolithic Power Systems, Inc. designs, develops, and markets integrated power semiconductor solutions and power delivery architectures for consumer, industrial, computing and storage, and communications market divisions. The company has market cap of $4.55 billion. It offers direct current to DC converter integrated circuits (ICs) that are used to convert and control voltages of various electronic systems, such as portable electronic devices, wireless LAN access points, computers, monitors, automobiles, and medical equipment. It has a 68.08 P/E ratio. The firm also provides lighting control ICs for backlighting that are used in systems, which provide the light source for LCD panels in notebook computers, monitors, car navigation systems, and televisions, as well as for general illumination applications.

Analysts await Monolithic Power Systems, Inc. (NASDAQ:MPWR) to report earnings on February, 8. They expect $0.53 EPS, up 32.50% or $0.13 from last year’s $0.4 per share. MPWR’s profit will be $22.01 million for 51.67 P/E if the $0.53 EPS becomes a reality. After $0.55 actual EPS reported by Monolithic Power Systems, Inc. for the previous quarter, Wall Street now forecasts -3.64% negative EPS growth.

Among 10 analysts covering Monolithic Power Systems (NASDAQ:MPWR), 10 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Monolithic Power Systems has $14000 highest and $61 lowest target. $116’s average target is 5.90% above currents $109.54 stock price. Monolithic Power Systems had 34 analyst reports since August 31, 2015 according to SRatingsIntel. As per Tuesday, November 1, the company rating was maintained by Stifel Nicolaus. The rating was maintained by Deutsche Bank on Tuesday, October 24 with “Buy”. KeyBanc Capital Markets maintained Monolithic Power Systems, Inc. (NASDAQ:MPWR) on Monday, October 16 with “Buy” rating. Needham maintained the stock with “Buy” rating in Thursday, July 27 report. The stock of Monolithic Power Systems, Inc. (NASDAQ:MPWR) earned “Buy” rating by Stifel Nicolaus on Friday, September 1. Oppenheimer maintained Monolithic Power Systems, Inc. (NASDAQ:MPWR) rating on Tuesday, May 3. Oppenheimer has “Outperform” rating and $80 target. The stock of Monolithic Power Systems, Inc. (NASDAQ:MPWR) has “Buy” rating given on Tuesday, June 13 by Oppenheimer. The rating was maintained by William Blair on Monday, August 31 with “Outperform”. The company was maintained on Tuesday, October 27 by Oppenheimer. On Friday, October 27 the stock rating was maintained by Oppenheimer with “Outperform”.